Lybalvi

Chemical Nameolanzapine and samidorphan
Dosage FormTablets (oral; 5 mg/10 mg, 10 mg/10 mg, 15 mg/10 mg, 20 mg/10 mg)
Drug ClassReceptor antagonists
SystemNervous
CompanyAlkermes Inc.
Approval Year2021

Indication

  • For the treatment of Schizophrenia in adults.
  • For the treatment of Bipolar I disorder (acute treatment of manic or mixed episodes as monotherapy, as adjunct to lithium or maintenance monotherapy treatment) in adults.
Last updated on 10/4/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Lybalvi (olanzapine and samidorphan) Prescribing Information2021Alkermes Inc., Waltham, MA